Shanghai BDgene Technology Co., Ltd., a China-based specialist in gene therapy, has entered into a strategic partnership with SPH RD, a wholly owned subsidiary of Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607, HKG: 2607). This collaboration aims to leverage BDgene’s advanced carrier technology and gene therapy R&D achievements alongside SPH RD’s clinical research capabilities and resource aggregation.
The partnership will focus on deepening cooperation in drug clinical research and development, with the goal of accelerating the commercial development and industrial transformation of gene therapy projects. Together, they aim to facilitate the translation of scientific research into practical applications, expedite the launch of innovative drugs, and continuously address patient needs.- Flcube.com
